Solid Biosciences Inc
Company Profile
Business description
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company’s singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Contact
500 Rutherford Avenue
Third Floor
CharlestownMA02129
USAT: +1 617 337-4680
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
100
Stocks News & Analysis
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
stocks
Cheap ASX energy play boasts strong cash flows and balance sheet
stocks
Market overreacts to earnings miss from moated ASX retailer
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,245.00 | 45.00 | -0.48% |
| CAC 40 | 7,843.04 | 126.65 | -1.59% |
| DAX 40 | 24,273.12 | 89.97 | -0.37% |
| Dow JONES (US) | 45,282.47 | 349.27 | -0.77% |
| FTSE 100 | 9,321.40 | 12.20 | 0.13% |
| HKSE | 25,829.91 | 725.30 | 2.89% |
| NASDAQ | 21,449.29 | 47.24 | -0.22% |
| Nikkei 225 | 42,807.82 | 197.65 | 0.46% |
| NZX 50 Index | 13,081.07 | 1.57 | 0.01% |
| S&P 500 | 6,439.32 | 27.59 | -0.43% |
| S&P/ASX 200 | 8,972.40 | 52.00 | -0.58% |
| SSE Composite Index | 3,883.56 | 57.80 | 1.51% |